神经肽 Y 受体：癌症成像和治疗的有前途的靶点。
Neuropeptide Y receptors: a promising target for cancer imaging and therapy.
机构信息
Key Laboratory of Magnetic Materials and Devices & Division of Functional Materials and Nano Devices, Ningbo Institute of Materials Technology & Engineering, Chinese Academy of Sciences, Ningbo 315201, China.
出版信息
Regen Biomater. 2015 Sep;2(3):215-9. doi: 10.1093/rb/rbv013. Epub 2015 Aug 7.
Abstract
Neuropeptide Y (NPY) was first identified from porcine brain in 1982, and plays its biological functions in humans through NPY receptors (Y1, Y2, Y4 and Y5). NPY receptors are known to mediate various physiological functions and involve in a majority of human diseases, such as obesity, hypertension, epilepsy and metabolic disorders. Recently, NPY receptors have been found to be overexpressed in many cancers, so they emerged as promising target in cancer diagnosis and therapy. This review focuses on the latest research about NPY and NPY receptors, and summarizes the current knowledge on NPY receptors expression in cancers, selective ligands for NPY receptors and their application in cancer imaging and therapy.
摘要
神经肽 Y（NPY）于 1982 年首次从猪脑中被鉴定出来，通过 NPY 受体（Y1、Y2、Y4 和 Y5）在人体内发挥其生物学功能。已知 NPY 受体介导各种生理功能，并涉及大多数人类疾病，如肥胖、高血压、癫痫和代谢紊乱。最近，人们发现 NPY 受体在许多癌症中过度表达，因此它们成为癌症诊断和治疗有前途的靶点。本综述重点介绍了 NPY 和 NPY 受体的最新研究进展，总结了 NPY 受体在癌症中的表达、NPY 受体的选择性配体及其在癌症成像和治疗中的应用的现有知识。
相似文献
1
Neuropeptide Y receptors: a promising target for cancer imaging and therapy.神经肽 Y 受体：癌症成像和治疗的有前途的靶点。
Regen Biomater. 2015 Sep;2(3):215-9. doi: 10.1093/rb/rbv013. Epub 2015 Aug 7.
2
Regionally-selective down-regulation of NPY receptor subtypes in the obese Zucker rat. Relationship to the Y5 'feeding' receptor.肥胖 Zucker 大鼠中 NPY 受体亚型的区域选择性下调。与 Y5“进食”受体的关系。
Brain Res. 1997 May 30;758(1-2):17-25. doi: 10.1016/s0006-8993(97)00160-1.
3
A Promising Therapeutic Target for Metabolic Diseases: Neuropeptide Y Receptors in Humans.代谢性疾病的一个有前景的治疗靶点：人类神经肽Y受体
Cell Physiol Biochem. 2018;45(1):88-107. doi: 10.1159/000486225. Epub 2017 Dec 22.
4
Functional interaction between neuropeptide Y receptors and modulation of calcium channels in the rat hippocampus.大鼠海马体中神经肽Y受体之间的功能相互作用及钙通道的调节
Neuropharmacology. 2003 Feb;44(2):282-92. doi: 10.1016/s0028-3908(02)00382-9.
5
Characterization of a new neuropeptide Y Y5 agonist radioligand: [125I][cPP(1-7), NPY(19-23), Ala31, Aib32, Gln34]hPP.一种新型神经肽Y Y5激动剂放射性配体的表征：[125I][cPP(1-7)，NPY(19-23)，Ala31，Aib32，Gln34]hPP
Neuropeptides. 2004 Aug;38(4):163-74. doi: 10.1016/j.npep.2004.04.007.
6
Novel analogues of neuropeptide Y with a preference for the Y1-receptor.对Y1受体具有选择性的神经肽Y新型类似物。
Eur J Biochem. 2001 May;268(10):2828-37. doi: 10.1046/j.1432-1327.2001.02161.x.
7
Combined deletion of Y1, Y2, and Y4 receptors prevents hypothalamic neuropeptide Y overexpression-induced hyperinsulinemia despite persistence of hyperphagia and obesity.尽管存在食欲亢进和肥胖，但联合缺失Y1、Y2和Y4受体可预防下丘脑神经肽Y过表达诱导的高胰岛素血症。
Endocrinology. 2006 Nov;147(11):5094-101. doi: 10.1210/en.2006-0097. Epub 2006 Jul 27.
8
PET Imaging of the Neuropeptide Y System: A Systematic Review.正电子发射断层扫描成像的神经肽 Y 系统：系统评价。
Molecules. 2022 Jun 9;27(12):3726. doi: 10.3390/molecules27123726.
9
Expression of neuropeptide Y receptors mRNA and protein in human brain vessels and cerebromicrovascular cells in culture.神经肽Y受体mRNA和蛋白在人脑血管及培养的脑微血管细胞中的表达
J Cereb Blood Flow Metab. 1999 Feb;19(2):155-63. doi: 10.1097/00004647-199902000-00007.
10
Neuropeptide Y family receptors Y1 and Y2 from sea lamprey, Petromyzon marinus.海七鳃鳗（Petromyzon marinus）的神经肽Y家族受体Y1和Y2
Gen Comp Endocrinol. 2015 Oct 1;222:106-15. doi: 10.1016/j.ygcen.2015.08.005. Epub 2015 Aug 6.
引用本文的文献
1
Nanomaterial-assisted pancreatic cancer theranostics.纳米材料辅助的胰腺癌诊疗
Regen Biomater. 2025 Jun 11;12:rbaf054. doi: 10.1093/rb/rbaf054. eCollection 2025.
2
Neuropeptide Y in cancer-biological functions and potential clinical implications.癌症中的神经肽Y——生物学功能及潜在临床意义
Cancer Metastasis Rev. 2025 Jan 6;44(1):21. doi: 10.1007/s10555-024-10237-z.
3
Heterobivalent Dual-Target Peptide for Integrin-αβ and Neuropeptide Y Receptors on Breast Tumor.用于乳腺癌中整合素-αβ和神经肽Y受体的异二价双靶点肽
Pharmaceuticals (Basel). 2024 Oct 4;17(10):1328. doi: 10.3390/ph17101328.
4
Peptide-Drug Conjugates: Design, Chemistry, and Drug Delivery System as a Novel Cancer Theranostic.肽-药物偶联物：作为一种新型癌症诊疗手段的设计、化学及药物递送系统
ACS Pharmacol Transl Sci. 2024 Jan 24;7(2):309-334. doi: 10.1021/acsptsci.3c00269. eCollection 2024 Feb 9.
5
The role of central neurotransmitters in appetite regulation of broilers and layers: similarities and differences.中枢神经递质在肉鸡和蛋鸡食欲调节中的作用：相似性和差异性。
Vet Res Commun. 2024 Jun;48(3):1313-1328. doi: 10.1007/s11259-024-10312-4. Epub 2024 Jan 29.
6
Neuropeptide Y Peptide Family and Cancer: Antitumor Therapeutic Strategies.神经肽 Y 肽家族与癌症：抗肿瘤治疗策略。
Int J Mol Sci. 2023 Jun 9;24(12):9962. doi: 10.3390/ijms24129962.
7
Pharmacological inhibition of neuropeptide Y receptors Y1 and Y5 reduces hypoxic breast cancer migration, proliferation, and signaling.神经肽 Y 受体 Y1 和 Y5 的药理学抑制可减少低氧乳腺癌的迁移、增殖和信号转导。
BMC Cancer. 2023 Jun 1;23(1):494. doi: 10.1186/s12885-023-10993-1.
8
Transformable Neuropeptide Prodrug with Tumor Microenvironment Responsiveness for Tumor Growth and Metastasis Inhibition of Triple-Negative Breast Cancer.可变形神经肽前药具有肿瘤微环境响应性，可抑制三阴性乳腺癌的肿瘤生长和转移。
Adv Sci (Weinh). 2023 Jul;10(21):e2300545. doi: 10.1002/advs.202300545. Epub 2023 May 5.
9
An Overview of the Molecular Cues and Their Intracellular Signaling Shared by Cancer and the Nervous System: From Neurotransmitters to Synaptic Proteins, Anatomy of an All-Inclusive Cooperation.癌症与神经系统共享的分子线索及其细胞内信号概述：从神经递质到突触蛋白，全面合作的解剖结构。
Int J Mol Sci. 2022 Nov 24;23(23):14695. doi: 10.3390/ijms232314695.
10
Correlation of Transcriptomics and FDG-PET SUVmax Indicates Reciprocal Expression of Stemness-Related Transcription Factor and Neuropeptide Signaling Pathways in Glucose Metabolism of Ewing Sarcoma.转录组学与FDG-PET SUVmax的相关性表明，尤因肉瘤葡萄糖代谢中干性相关转录因子和神经肽信号通路呈相互表达。
Cancers (Basel). 2022 Dec 5;14(23):5999. doi: 10.3390/cancers14235999.
本文引用的文献
1
Controlling toxicity of Peptide-drug conjugates by different chemical linker structures.通过不同化学连接子结构控制肽-药物偶联物的毒性
ChemMedChem. 2015 May;10(5):804-14. doi: 10.1002/cmdc.201402514. Epub 2015 Apr 9.
2
Synthesis and in vitro and in vivo evaluation of an (18)F-labeled neuropeptide Y analogue for imaging of breast cancer by PET.一种用于正电子发射断层显像（PET）乳腺癌成像的（18）F标记神经肽Y类似物的合成及其体外和体内评价
Mol Pharm. 2015 Apr 6;12(4):1121-30. doi: 10.1021/mp500601z. Epub 2015 Mar 13.
3
Drug delivery and release systems for targeted tumor therapy.用于靶向肿瘤治疗的药物递送与释放系统。
J Pept Sci. 2015 Mar;21(3):186-200. doi: 10.1002/psc.2753. Epub 2015 Feb 23.
4
Neuropeptide Y Y1 receptors mediate [corrected] targeted delivery of anticancer drug with encapsulated nanoparticles to breast cancer cells with high selectivity and its potential for breast cancer therapy.神经肽Y Y1受体介导[已修正]用包封纳米颗粒将抗癌药物靶向递送至乳腺癌细胞，具有高选择性及其在乳腺癌治疗中的潜力。
ACS Appl Mater Interfaces. 2015 Mar 11;7(9):5574-82. doi: 10.1021/acsami.5b00270. Epub 2015 Feb 26.
5
Receptor-mediated uptake of boron-rich neuropeptide y analogues for boron neutron capture therapy.用于硼中子俘获治疗的富含硼的神经肽Y类似物的受体介导摄取。
ChemMedChem. 2015 Jan;10(1):164-72. doi: 10.1002/cmdc.201402368. Epub 2014 Oct 22.
6
Nanotechnology and tumor microcirculation.纳米技术与肿瘤微循环。
Adv Drug Deliv Rev. 2014 Jul;74:2-11. doi: 10.1016/j.addr.2013.08.010. Epub 2013 Aug 30.
7
Neuropeptide Y receptors: how to get subtype selectivity.神经肽 Y 受体：如何获得亚型选择性。
Front Endocrinol (Lausanne). 2013 Feb 4;4:5. doi: 10.3389/fendo.2013.00005. eCollection 2013.
8
Heterobivalent dual-target probe for targeting GRP and Y1 receptors on tumor cells.用于针对肿瘤细胞上的 GRP 和 Y1 受体的异价双靶探针。
Bioorg Med Chem Lett. 2013 Feb 1;23(3):687-92. doi: 10.1016/j.bmcl.2012.11.110. Epub 2012 Dec 5.
9
High expression of NPY receptors in the human testis.人睾丸中 NPY 受体的高表达。
Mol Cell Endocrinol. 2011 Apr 30;337(1-2):62-70. doi: 10.1016/j.mce.2011.01.021. Epub 2011 Feb 2.
10
Ligand-induced internalization and recycling of the human neuropeptide Y2 receptor is regulated by its carboxyl-terminal tail.配体诱导的人神经肽 Y2 受体的内化和再循环受其羧基末端尾部调节。
J Biol Chem. 2010 Dec 31;285(53):41578-90. doi: 10.1074/jbc.M110.162156. Epub 2010 Oct 18.
Zotero 插件